Vardenafil in the treatment of erectile dysfunction in outpatients with chronic schizophrenia: A flexible-dose, open-label study

Journal of Clinical Psychiatry

Volumn 69, Issue 2, 2008, Pages 206-212

  Mitsonis, Charalampos I ^a,b,d   Mitropoulos, Panagiotis A ^c   Dimopoulos, Nikolaos P ^a,c   Kararizou, Evangelia G ^b   Psarra, Vasiliki V ^a   Tsakiris, Fivos E ^a   Katsanou, Maria Nefeli E ^a  

^a Psychiatric Hospital of Athens   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF PATRAS   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ARIPIPRAZOLE; BIPERIDEN; BROMOCRIPTINE MESILATE; CLOZAPINE; DIAZEPAM; HALOPERIDOL; OLANZAPINE; PHOSPHODIESTERASE V INHIBITOR; PROLACTIN; RISPERIDONE; SILDENAFIL; VARDENAFIL;

ADULT; ARTICLE; CHRONIC DISEASE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ERECTILE DYSFUNCTION; GREECE; HEADACHE; HOT FLUSH; HUMAN; INCIDENCE; INTERNATIONAL INDEX OF ERECTILE FUNCTION; MAJOR CLINICAL STUDY; MALE; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; OUTPATIENT; PENIS ERECTION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; QUALITY OF LIFE; QUALITY OF LIFE SCALE; RATING SCALE; SCHIZOPHRENIA; SEXUAL FUNCTION; SEXUAL INTERCOURSE; SEXUAL SATISFACTION; TREATMENT RESPONSE;

EID: 41549095503     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n0206     Document Type: Article

References (34)

1. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999;84:50-56
2. Lue TF. Erectile dysfunction. N Engl J Med 2000;342:1802-1813
3. Macdonald S, Halliday J, MacEwan T, et al. Nithsdale Schizophrenia Surveys 24: sexual dysfunction: case-control study. Br J Psychiatry 2003;182:50-56
4. Dossenbach M, Hodge A, Anders M, et al. Prevalence of sexual dysfunction in patients with schizophrenia: international variation and underestimation. Int J Neuropsychopharmacol 2005;8:195-201
5. Dossenbach M, Dyachkova Y, Pirildar S, et al. Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Eur Psychiatry 2006;21:251-258
6. Olfson M, Uttaro T, Carson WH, et al. Male sexual dysfunction and quality of life in schizophrenia. J Clin Psychiatry 2005;66:331-338
7. Aizenberg D, Zemishlany Z, Dorfman-Etrog P, et al. Sexual dysfunction in male schizophrenic patients. J Clin Psychiatry 1995;56:137-141
8. Smith SM, O'Keane V, Murray R. Sexual dysfunction in patients taking conventional antipsychotic medication. Br J Psychiatry 2002;181:49-55
9. Wirshing DA, Pierre JM, Marder SR, et al. Sexual side effects of novel antipsychotic medications. Schizophr Res 2002;56:25-30
10. Byerly MJ, Nakonezny PA, Bettcher BM, et al. Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine. Schizophr Res 2006;86:244-250
11. Haupt DW. Differential metabolic effects of antipsychotic treatments. Eur Neuropsychopharmacol 2006;16(suppl 3):S149-S155
12. Valevski A, Modai I, Zbarski E, et al. Effect of amantadine on sexual dysfunction in neuroleptic-treated male schizophrenic patients. Clin Neuropharmacol 1998;21:355-357
13. Aversa A, Bruzziches R, Pili M, et al. Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction. Curr Pharm Des 2006;12:3467-3484
14. Sommer F. Potency and selectivity of vardenafil: a phosphodiesterase Type 5 inhibitor. Expert Opin Drug Metab Toxicol 2005;1:295-301
15. Aviv A, Shelef A, Weizman A. An open-label trial of sildenafil addition in risperidone-treated male schizophrenia patients with erectile dysfunction. J Clin Psychiatry 2004;65:97-103
16. Benatov R, Reznik I, Zemishlany Z. Sildenafil citrate (Viagra) treatment of sexual dysfunction in a schizophrenic patient. Eur Psychiatry 1999;14:353-355
17. Segraves RT. Two additional uses for sildenafil in psychiatric patients [letter]. J Sex Marital Ther 1999;25:265-266
18. Lare SB, Labbate LA. Sildenafil and erectile dysfunction [letter]. Am J Psychiatry 2000;157:2055-2056
19. Gopalakrishnan R, Jacob KS, Kuruvilla A, et al. Sildenafil in the treatment of antipsychotic-induced erectile dysfunction: a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial. Am J Psychiatry 2006;163:494-499
20. Eardley I. Vardenafil: a new oral treatment for erectile dysfunction. Int J Clin Pract 2004;58:801-806
21. Rosen R, Shabsigh R, Berber M, et al. Efficacy and tolerability of vardenafil in men with mild depression and erectile dysfunction: the depression-related improvement with vardenafil for erectile response study. Am J Psychiatry 2006;163:79-87
22. Saenz de Tejada I, Angulo J, Cuevas P, et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 2001;13:282-290
23. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
24. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276
25. Rosen RC, Riley A, Wagner G, et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-830
26. Cappelleri JC, Rosen RC, Smith MD, et al. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999;54:346-351
27. Heinrichs DW, Hanlon TE, Carpenter WT Jr. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984;10:388-398
28. Hatzichristou D, Cuzin B, Martin-Morales A, et al. Vardenafil improves satisfaction rates, depressive symptomatology, and self-confidence in a broad population of men with erectile dysfunction. J Sex Med 2005;2:109-116
29. Giuliano F, Rubio-Aurioles E, Kennelly M, et al. Efficacy and safety of vardenafil in men with erectile dysfunction caused by spinal cord injury. Neurology 2006;66:210-216
30. Goldstein I, Young JM, Fischer J, et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003;26:777-783
31. Nehra A, Grantmyre J, Nadel A, et al. Vardenafil improved patient satisfaction with erectile hardness, orgasmic function and sexual experience in men with erectile dysfunction following nerve sparing radical prostatectomy. J Urol 2005;173:2067-2071
32. Mitsonis CI, Dimopoulos NP, Mitropoulos PA, et al. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: an open-label pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:373-377
33. Lyketsos GC, Sakka P, Mailis A. The sexual adjustment of chronic schizophrenics: a preliminary study. Br J Psychiatry 1983;143:376-382
34. Howes OD, Smith S, Aitchison KJ. Comments on "Prolactin levels and erectile function in patients treated with risperidone" (J Clin Psychopharmacol 2004;24:161-166) [letter]. J Clin Psychopharmacol 2005;25:393-394